Healthcare Services

Global Onychomycosis Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Onychomycosis Market Expected To Change Between 2026 And 2030?

The onychomycosis market size has exhibited substantial expansion in recent years. It is anticipated to expand from $3.81 billion in 2025 to $4.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historical growth can be ascribed to several factors, including the significant prevalence of onychomycosis, a restricted supply of advanced antifungal medications, an increase in fungal nail infections driven by an aging population, heightened awareness among dermatologists, and the prompt integration of topical treatments.

The onychomycosis market is projected to experience substantial expansion in the coming years, reaching a valuation of $5.09 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This projected growth during the forecast period is primarily driven by several factors, including an escalating demand for combined treatment approaches, the increasing integration of teledermatology and remote patient monitoring, the progressing creation of AI-powered diagnostic tools, the broadening reach of hospital and retail pharmacy networks, and heightened investment in research targeting drug-resistant fungal strains. Key trends anticipated within this period encompass the growing preference for tailored antifungal treatments, the expanded application of teledermatology for both diagnosis and ongoing monitoring, the increasing deployment of AI-based diagnostic instruments specifically for nail infections, a heightened public awareness regarding nail health and proper hygiene practices, and the continuous advancement of combined drug and topical therapeutic solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp

What Underlying Factors Are Accelerating The Growth Of The Onychomycosis Market?

The increasing diabetic patient population is projected to fuel expansion in the onychomycosis market moving ahead. Diabetes, a chronic disease, results from either inadequate insulin production by the pancreas or inefficient insulin utilization by the body. For individuals with diabetes, onychomycosis is a prevalent foot ailment, which can be managed by preventing and handling associated complications. Consequently, the growing occurrence of diabetes stimulates demand within the onychomycosis market. As an illustration, the National Health Service, a UK-based government department, reported in June 2024 that in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This figure indicates a significant increase compared to 3,065,825 in 2022, representing an almost 20% rise. Thus, the escalating incidence of diabetes is a primary driver for the growth of the onychomycosis market.

How Is The Onychomycosis Market Structured Across Different Segments?

The onychomycosis market covered in this report is segmented –

1) By Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types

2) By Treatment: Drug Treatment, Topical Therapy, Other Treatments

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections, Mixed Infections

2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections

3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis, Fungal Infections In Immunocompromised Patients

4) By Candida Onychomycosis: Candidal Nail Infections, Mixed Fungal-Candida Infections

5) By Other Types: Total Nail Dystrophy, Secondary Onychomycosis

How Are Trends Impacting The Onychomycosis Market?

Leading companies in the onychomycosis market are developing innovative product formulations to maintain their market position. These inventive formulations contribute to the progress of the onychomycosis market by enhancing treatment outcomes and addressing specific challenges related to the condition. For instance, in February 2024, Moberg Pharma AB, a pharmaceutical firm based in Sweden, introduced MOB-015. This is a unique topical formulation of terbinafine, engineered to deliver effective concentrations directly to the nail and nail bed, thereby minimizing the systemic exposure risk associated with oral terbinafine. It has garnered recommendations for national approval in 13 European countries and is sold in Sweden under the brand name Terclara. The approval is underpinned by two Phase 3 trials, which indicated that MOB-015 achieved superior mycological cure rates (76% in contrast to up to 42% for comparators) and a significantly higher complete cure rate, with no serious adverse reactions documented.

Which Major Players Dominate The Onychomycosis Market?

Major companies operating in the onychomycosis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

Read the full onychomycosis market report here:

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Which Region Is Projected To Dominate The Onychomycosis Market During The Forecast Period?

North America was the largest region in the onychomycosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Onychomycosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12197&type=smp

Browse Through More Reports Similar to the Global Onychomycosis Market 2026, By The Business Research Company

Interactive Fitness Global Market Report

https://www.thebusinessresearchcompany.com/report/interactive-fitness-global-market-report

Virtual Reality Vr Fitness Game Global Market Report

https://www.thebusinessresearchcompany.com/report/virtual-reality-vr-fitness-game-global-market-report

Fitness App Global Market Report

https://www.thebusinessresearchcompany.com/report/fitness-app-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795